Abstract
Recombinant immunotoxins are extremely promising agents for the targeted therapy of tumors with a certain molecular profile. In this work, we studied the properties of a new recombinant HER2-specific immunotoxin composed of the scFv antibody and a fragment of Pseudomonas exotoxin A (4D5scFv-PE40). High affinity of the immunotoxin for the HER2 tumor marker, its selective cytotoxicity against HER2-overexpressing cells, and its storage stability were demonstrated. The 50% inhibitory concentration (IC50) of the 4D5scFv-PE40 immunotoxin for HER2-overexpressing cancer cells was 2.5-3 orders of magnitude lower compared to that for CHO cells not expressing this tumor marker and was 2.5-3 orders of magnitude lower than IC50 of free PE40 for HER2-overexpressing cancer cells. These findings provide a basis for expecting in the long run high therapeutic index values of the 4D5scFv-PE40 immunotoxin for its use in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 93-96 |
| Number of pages | 4 |
| Journal | Acta Naturae |
| Volume | 7 |
| Issue number | 4 |
| Publication status | Published - 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- 4D5scFv
- HER2 tumor marker
- Pseudomonas exotoxin A
- Recombinant immunotoxin
- Targeted therapy
ASJC Scopus subject areas
- Biochemistry
- Biotechnology
- Molecular Biology
- Molecular Medicine
Cite this
Recombinant immunotoxin 4D5scFv-PE40 for targeted therapy of HER2-positive tumors. / Sokolova, E. A.; Stremovskiy, O. A.; Zdobnova, T. A.; Balalaeva, I. V.; Deyev, S. M.
In: Acta Naturae, Vol. 7, No. 4, 2015, p. 93-96.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recombinant immunotoxin 4D5scFv-PE40 for targeted therapy of HER2-positive tumors
AU - Sokolova, E. A.
AU - Stremovskiy, O. A.
AU - Zdobnova, T. A.
AU - Balalaeva, I. V.
AU - Deyev, S. M.
PY - 2015
Y1 - 2015
N2 - Recombinant immunotoxins are extremely promising agents for the targeted therapy of tumors with a certain molecular profile. In this work, we studied the properties of a new recombinant HER2-specific immunotoxin composed of the scFv antibody and a fragment of Pseudomonas exotoxin A (4D5scFv-PE40). High affinity of the immunotoxin for the HER2 tumor marker, its selective cytotoxicity against HER2-overexpressing cells, and its storage stability were demonstrated. The 50% inhibitory concentration (IC50) of the 4D5scFv-PE40 immunotoxin for HER2-overexpressing cancer cells was 2.5-3 orders of magnitude lower compared to that for CHO cells not expressing this tumor marker and was 2.5-3 orders of magnitude lower than IC50 of free PE40 for HER2-overexpressing cancer cells. These findings provide a basis for expecting in the long run high therapeutic index values of the 4D5scFv-PE40 immunotoxin for its use in vivo.
AB - Recombinant immunotoxins are extremely promising agents for the targeted therapy of tumors with a certain molecular profile. In this work, we studied the properties of a new recombinant HER2-specific immunotoxin composed of the scFv antibody and a fragment of Pseudomonas exotoxin A (4D5scFv-PE40). High affinity of the immunotoxin for the HER2 tumor marker, its selective cytotoxicity against HER2-overexpressing cells, and its storage stability were demonstrated. The 50% inhibitory concentration (IC50) of the 4D5scFv-PE40 immunotoxin for HER2-overexpressing cancer cells was 2.5-3 orders of magnitude lower compared to that for CHO cells not expressing this tumor marker and was 2.5-3 orders of magnitude lower than IC50 of free PE40 for HER2-overexpressing cancer cells. These findings provide a basis for expecting in the long run high therapeutic index values of the 4D5scFv-PE40 immunotoxin for its use in vivo.
KW - 4D5scFv
KW - HER2 tumor marker
KW - Pseudomonas exotoxin A
KW - Recombinant immunotoxin
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84952013373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952013373&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84952013373
VL - 7
SP - 93
EP - 96
JO - Acta Naturae
JF - Acta Naturae
SN - 2075-8251
IS - 4
ER -